News | July 28, 2022
Velocity Clinical Research begins European expansion with German site acquisition
Biopharma and CROs to benefit from simplified access to global research sites
Biopharma and CROs to benefit from simplified access to global research sites
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Subscribe To Our Newsletter & Stay Updated
